Financial and Corporate Situation - AB Science reported a reduced operating deficit of €2.7 million for the first half of 2025, a decrease of 24% compared to €3.6 million in the same period of 2024 [4][3] - The company raised €6.3 million through private placements to support ongoing activities, particularly the clinical development of the AB8939 program [25] - The net loss for the first half of 2025 was €5.2 million, an increase of 15.8% from a loss of €4.5 million in the first half of 2024 [6][7] Clinical Development - AB Science received authorization from several European countries for a Phase 3 confirmatory study with masitinib in amyotrophic lateral sclerosis (ALS) [8] - The FDA and EMA approved a Phase 3 confirmatory study with masitinib in metastatic hormone-resistant prostate cancer [13] - New data indicated the efficacy of masitinib in treating Alzheimer's disease, showing improvements in cognitive and behavioral symptoms in a mouse model [15][16] - The AB8939 molecule received orphan drug designation from the EMA for the treatment of acute myeloid leukemia (AML) [21] - A Canadian patent was granted for AB8939, providing protection until 2036 [23] Financial Results Summary - Operating income was €515 thousand, down from €560 thousand in the first half of 2024, attributed to a temporary decline in sales of veterinary medicine [5][7] - Operating expenses decreased by 21.7%, with administrative expenses down by 31.1% [5] - Financial income for the first half of 2025 was €212 thousand, while financial expenses amounted to €2.7 million [7]

Core Points - AB Science has announced the issuance of a Canadian patent for AB8939, which protects its composition and use in treating acute myeloid leukemia (AML) until 2036 [1] - The patent completes the intellectual property coverage for AB8939 across all key geographic areas, including Europe, USA, China, Japan, South Korea, India, Israel, Latin America, and Australia [2] - AB8939 is a novel microtubule destabilizer currently in early phase clinical trials for AML, with the first phase focusing on determining the maximum tolerated dose [3] - The drug is also eligible for regulatory data protection in Canada, preventing generic competition for 8 years post-approval, and has received orphan drug designation from EMA and FDA, providing additional market exclusivity [4] - A separate patent application has been filed to protect AB8939 for treating AML with specific chromosomal abnormalities, potentially extending protection until 2044 [5] - AB8939 targets cancer cells by destabilizing microtubules and inhibiting enzymes essential for cancer stem cell survival [6] - AB Science specializes in developing protein kinase inhibitors for diseases with high unmet medical needs and has a portfolio of molecules including masitinib [7][8]

Core Points - The European Medicine Agency (EMA) has approved the extension of the shelf-life of AB Science's veterinary medicine MASIVET® from 36 months to 48 months [1] - MASIVET® is approved for treating non-resectable dog mast cell tumors (Grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor and is available in all EU countries [2] - The shelf-life extension provides flexibility for patients, caregivers, and AB Science in managing inventory levels, reducing the risk of product expiration, and ensuring continuity of therapies [3] Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [4] - The company's lead compound, masitinib, is registered for veterinary medicine and is also being developed for human medicine in various fields including oncology and neurological diseases [5]

Company Announcement - AB Science SA has postponed the publication of its 2024 annual financial report from April 30, 2025, to May 9, 2025, to allow auditors to complete their work [1][2] Company Overview - AB Science, founded in 2001, is a pharmaceutical company focused on the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [3] - The company's lead compound, masitinib, is registered for veterinary medicine and is being developed for human medicine in areas such as oncology, neurological diseases, inflammatory diseases, and viral diseases [4] Additional Information - AB Science is headquartered in Paris, France, and is listed on Euronext Paris under the ticker AB [4] - Further information can be found on the company's website [5]